Wells Fargo & Company Xilio Therapeutics, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.55 - $1.08 $1 - $2	2 Added 1.89%	108 $0
Q4 2023 Feb 09, 2024	BUY	$0.5 - $2.5 $3 - $15	6 Added 6.0%	106 $0
Q3 2023 Nov 13, 2023	BUY	$2.11 - $2.9 $40 - $55	19 Added 23.46%	100 $0
Q2 2023 Aug 15, 2023	BUY	$2.55 - $3.46 $7 - $10	3 Added 3.85%	81 $0
Q1 2023 May 12, 2023	BUY	$2.66 - $4.28 $2 - $4	1 Added 1.3%	78 $0
Q4 2022 Feb 13, 2023	BUY	$1.97 - $3.03 $3 - $6	2 Added 2.67%	77 $0
Q3 2022 Nov 14, 2022	BUY	$2.07 - $3.44 $49 - $82	24 Added 47.06%	75 $0
Q2 2022 Aug 12, 2022	SELL	$2.08 - $7.2 $3,352 - $11,606	-1,612 Reduced 96.93%	51 $0
Q1 2022 May 16, 2022	SELL	$6.63 - $16.05 $18,557 - $44,923	-2,799 Reduced 62.73%	1,663 $12,000
Q4 2021 Feb 14, 2022	BUY	$9.69 - $25.11 $43,236 - $112,040	4,462 New	4,462 $71,000

14M

Ticker XLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,471,600
Market Cap $30.8M
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.